Sleep Number Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board refreshment, cost reductions, and major product resets. Key governance proposals failed to pass, while director elections, auditor ratification, executive compensation, and an equity plan amendment were approved.
-
Q1 2026 net sales reached $319 million, with adjusted EBITDA ahead of plan despite a 19% year-over-year decline. Liquidity improved with a $55 million infusion, and new products drove higher ARU and customer satisfaction. Gross margin was 57.9%, with cost savings and strategic review ongoing.
-
A new CEO has driven major cost reductions, management changes, and product innovation, including a new entry-level bed and modernized marketing. The company is optimizing its store footprint, improving financial flexibility, and targeting growth among value-focused and wellness-oriented customers.
Fiscal Year 2025
-
2025 saw a successful turnaround with cost reductions, a new product lineup, and improved margins despite lower sales. Liquidity remains a focus, with double-digit sales growth and higher EBITDA expected in the second half of 2026.
-
Q3 sales fell 19.6% year over year amid aggressive competition and reduced marketing spend, but cost reductions and a new bank agreement provide flexibility for turnaround efforts. 2025 guidance includes $1.4B in sales, 60% gross margin, and negative $50M free cash flow, with 2026 focused on growth and further cost cuts.
-
Q2 net sales fell 19.7% year-over-year to $328 million due to a strategic marketing reset, but gross margin held steady at 59.1%. Cost reductions exceeded targets, with $130 million in annualized savings expected for 2025. Full-year sales are forecast to decline 14% to $1.45 billion.
-
Q1 net sales fell 16% year-over-year, but gross margin improved to 61.2% due to operational efficiencies. Leadership is executing $80–$100 million in annualized cost reductions, restructuring, and a renewed focus on core customer value, while navigating tariff and demand headwinds.
Fiscal Year 2024
-
Leadership transition is underway as the company delivered strong margin and cost improvements despite an 11% sales decline in 2024. Adjusted EBITDA rose 43% in Q4, and operational efficiencies offset weak demand, with further cost actions and debt restructuring planned.
-
Q3 saw a 10% sales decline but strong gross margin gains and cost reductions, with adjusted EBITDA up 11% year-over-year. Full-year guidance was lowered due to persistent weak demand, but the company remains focused on innovation, cost control, and maintaining covenant compliance.
-
Q2 saw net sales down 11% year-over-year, but gross margin improved 150 bps and cost reductions drove better-than-expected Adjusted EBITDA. Full-year guidance is maintained despite ongoing industry demand pressures, with innovation and operational transformation supporting future growth.